Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives Orphan Drug Status for Amyloidosis Drug


Alnylam Pharmaceuticals said this week that the US Food and Drug Administration has given orphan drug status to the company's investigational transthyretin-mediated amyloidosis ALN-TTR02 as a treatment for familial amyloidotic polyneuropathy, a common manifestation of the disease.

The designation provides a drugmaker with, among other things, extended market exclusivity for its product, tax credits, and marketing incentives.

ALN-TTR02 recently entered phase II testing (GSN 6/7/2012).